- Odermatt stays hot to break Swiss World Cup wins record
- Neville says Rashford's career at Man Utd nearing 'inevitable ending'
- Syria's new leader vows not to negatively interfere in Lebanon
- Germany pledges security inquest after Christmas market attack
- Putin vows 'destruction' on Ukraine after Kazan drone attack
- Understated Usyk seeks recognition among boxing legends
- France awaits appointment of new government
- Cyclone Chido death toll rises to 94 in Mozambique
- Stokes out of England's Champions Trophy squad
- Gaza rescuers say Israeli strikes kill 28
- Sweet smell of success for niche perfumes
- 'Finally, we made it!': Ho Chi Minh City celebrates first metro
- Angry questions in Germany after Christmas market attack
- China's Zheng pulls out of season-opening United Cup
- Minorities fear targeted attacks in post-revolution Bangladesh
- Tatum's 43-point triple-double propels Celtics over Bulls
- Tunisia women herb harvesters struggle with drought and heat
- Trump threatens to take back control of Panama Canal
- India's architecture fans guard Mumbai's Art Deco past
- Secretive game developer codes hit 'Balatro' in Canadian prairie province
- Large earthquake hits battered Vanuatu
- Beaten Fury says Usyk got 'Christmas gift' from judges
- First Singaporean golfer at Masters hopes 'not be in awe' of heroes
- Usyk beats Fury in heavyweight championship rematch
- Stellantis backtracks on plan to lay off 1,100 at US Jeep plant
- Atletico snatch late win at Barca to top La Liga
- Australian teen Konstas ready for Indian pace challenge
- Strong quake strikes off battered Vanuatu
- Tiger Woods and son Charlie share halfway lead in family event
- Bath stay out in front in Premiership as Bristol secure record win
- Mahomes shines as NFL-best Chiefs beat Texans to reach 14-1
- Suspect in deadly Christmas market attack railed against Islam, Germany
- MLB legend Henderson, career stolen base leader, dead at 65
- Albania announces shutdown of TikTok for at least a year
- Laboured Napoli take top spot in Serie A
- Schick hits four as Leverkusen close gap to Bayern on sombre weekend
- Calls for more safety measures after Croatia school stabbings
- Jesus double lifts Christmas spirits for five-star Arsenal
- Frankfurt miss chance to close on Bayern as attack victims remembered
- NBA fines Celtics coach Mazzulla and Nets center Claxton
- Banned Russian skater Valieva stars at Moscow ice gala
- Leading try scorer Maqala takes Bayonne past Vannes in Top 14
- Struggling Southampton appoint Juric as new manager
- Villa heap pain on slumping Man City as Forest soar
- Suspect in deadly Christmas market attack railed against Islam and Germany
- At least 32 die in bus accident in southeastern Brazil
- Freed activist Paul Watson vows to 'end whaling worldwide'
- Chinese ship linked to severed Baltic Sea cables sets sail
- Sorrow and fury in German town after Christmas market attack
- Guardiola vows Man City will regain confidence 'sooner or later' after another defeat
US panel weighs authorizing Covid vaccines for youngest children
After months of anxious wait for some parents, a panel of experts convened by the US Food and Drug Administration will meet Wednesday to weigh recommending Covid vaccines for the nation's youngest children.
Children under five are the only age group not yet eligible for Covid immunization in the United States and most other countries. If, as expected, panelists vote in favor of greenlighting the Pfizer and Moderna vaccines, formal authorizations should follow quickly, with the first shots in arms expected by next week.
Ahead of the meeting, the FDA posted its independent analyses of the two drugs, deeming both safe and effective. It also said there was a pressing unmet need to inoculate children in the age group since their rates of hospitalization and death "are higher than among children and adolescents 5-17 years of age."
Both vaccines are based on messenger RNA technology, which delivers genetic code for the coronavirus spike protein to human cells, training the immune system to be ready for when it encounters the real virus.
Pfizer is seeking authorization for three doses at three micrograms given to ages six months through four years, while Moderna has asked for the FDA to approve its vaccine as two doses of a higher 30 micrograms, for ages six months through five years.
They were tested in trials of thousands of children where they were found to have similar levels of mild effects to older age groups and triggered similar levels of antibodies.
Efficacy against infection was higher for Pfizer, with the company placing it at 80 percent compared to Moderna's estimates of 51 percent in the six-month-old to age two group and 37 percent in the two to five years age group.
But the figures are provisional and Moderna is studying adding a third dose later that may increase its figures.
There are some 20 million US children aged four years and under. If the FDA-appointed experts recommend the two vaccines, then the matter will go to another committee convened by the Centers for Disease Control and Prevention for a final say.
White House officials last week said the rollout of millions of shots at pharmacies and doctors' offices could begin as soon as June 21, following the Juneteenth holiday on June 20.
Of the total US Covid deaths, 480 have come in children under five, according to the latest official data.
Obesity, neurological disorders and asthma are associated with increased risk of severe disease, "however, a majority of children hospitalized for Covid-19 have no underlying medical conditions," the FDA said in a document.
Children can also go on to contract multisystem inflammatory syndrome in children (MIS-C), a rare but serious post-viral condition.
Data on long Covid in children is sparse, but the FDA's document cited a national survey in the United Kingdom which found that "among children ages two to 11 years who tested positive for COVID-19, 7.2 percent reported continued symptoms at 12 weeks."
E.Raimundo--PC